<DOC>
	<DOCNO>NCT02927873</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity respiratory syncytial virus ( RSV ) candidate vaccine first administer via intramuscular ( IM ) injection accord 0 , 1-month schedule RSV-seropositive infant age 12 17 month .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity GSK Biologicals ' RSV Investigational Vaccine RSV-seropositive Infants Aged 12 17 Months</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) / Legally acceptable representative ( LAR [ ] ) , opinion investigator , comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) subject prior performance study specific procedure . A male female , include , 12 17 month time first vaccination . Healthy subject establish medical history clinical examination enter study . Seropositive RSV determine IBL International kit . Born fullterm minimum birth weight 2.5 kg . Subjects ' parent ( ) /LAR ( ) need access consistent mean telephone contact computer . Child care . Use investigational nonregistered product study vaccine period start 30 day first dose study vaccine ( Day 29 Day 0 ) , plan use study period . Any medical condition judgment investigator would make IM injection unsafe . Chronic administration immunosuppressant immunemodifying drug period start six month prior first vaccine . For corticosteroid , mean prednisone , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug plan administration time study period . Administration immunoglobulins and/or blood product period start three month first dose study vaccine plan administration study period . Planned administration/administration vaccine foreseen study protocol period start 30 day first dose end 30 day last dose vaccine administration , exception schedule routine pediatric vaccine may administer ≥ 14 day dose ≥ 7 day dose . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Serious chronic illness . Major congenital defect . History neurological disorder seizure . History current autoimmune disease . History wheeze . History chronic cough . Previous hospitalization respiratory illness . History thrombocytopenia . History anemia . Previous , current plan administration Synagis . Neurological complication follow prior vaccination . Born mother know suspected HIVpositive . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . Previous vaccination recombinant simian human adenoviral vaccine . History reaction hypersensitivity likely exacerbate component vaccine . Hypersensitivity latex . Current severe eczema . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C/99.5°F oral , axillary tympanic route , ≥ 38.0°C/100.4°F rectal route . The preferred route record temperature study axillary . Clinically significant upper respiratory tract infection Subjects minor illness without fever may , enrol discretion investigator . Any clinically significant Grade 1 ≥ Grade 2 hematological biochemical laboratory abnormality detect last screening blood sample . Any condition investigator judge may interfere study procedure finding . Any condition could constitute risk subject participate study . Weight fifth percentile local weightforage curve . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Planned move location prohibit participate trial study end .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Respiratory syncytial virus ( RSV )</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Infants</keyword>
	<keyword>Vaccine</keyword>
</DOC>